Market Place
Sourcing Support
Coherus & Storm therapeutics to Test STC-15 + LOQTORZI in Combo
27 May 2025 //
GLOBENEWSWIRE
Coherus to Report Q1 2025 Financial Results on May 12, 2025
05 May 2025 //
GLOBENEWSWIRE
Coherus loses commercial chief amid exit from biosimilar space
24 Apr 2025 //
FIERCE BIOTECH
Coherus completes successful divestiture of Udenyca Franchise
14 Apr 2025 //
GLOBENEWSWIRE
Coherus repurchases $170M convertible notes
01 Apr 2025 //
GLOBENEWSWIRE
Coherus to Present Data on CHS-114 at 2025 AACR Annual Meeting
25 Mar 2025 //
GLOBENEWSWIRE
Coherus BioSciences Reports Q4, Full Year 2024 Financial Results
10 Mar 2025 //
GLOBENEWSWIRE
Coherus Presents Ph 2 Data On Casdozokitug Combo In Carcinoma
22 Jan 2025 //
GLOBENEWSWIRE
Coherus to Present Final Casdozokitug Data in Liver Cancer
18 Dec 2024 //
GLOBENEWSWIRE
Coherus Biosciences Sells Udenyca Franchise to Intas Pharma
04 Dec 2024 //
PRESS RELEASE
Coherus Faces Biosimilar Supply Issues Due To Manufacturer Problems
18 Sep 2024 //
FIERCE PHARMA
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh)
27 Jun 2024 //
GLOBENEWSWIRE
What Coherus` $40M sale of its Humira biosimilar says about the crowded market
27 Jun 2024 //
ENDPOINTS
Sandoz announces agreement to acquire CIMERLI® business from Coherus
22 Jan 2024 //
GLOBENEWSWIRE
Sandoz buys Coherus` Lucentis biosimilar Cimerli for $170M
22 Jan 2024 //
FIERCE PHARMA
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug
18 Jan 2024 //
GLOBENEWSWIRE
Coherus Announces FDA Approval of UDENYCA ONBODY™
26 Dec 2023 //
GLOBENEWSWIRE
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug
06 Dec 2023 //
GLOBENEWSWIRE
Coherus prices China-made PD-1 at 20% discount to Keytruda
27 Nov 2023 //
FIERCE PHARMA
Coherus Announces Resubmission of BLA Supplement for UDENYCA® ONBODY
05 Oct 2023 //
GLOBENEWSWIRE
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
04 Oct 2023 //
GLOBENEWSWIRE
Coherus and Superior Biologics Announce Distribution Agreement for YUSIMRY
13 Jul 2023 //
GLOBENEWSWIRE
Coherus BioSciences launches biosimilar version of AbbVie`s blockbuster Humira
04 Jul 2023 //
YAHOO FINANCE
AbbVie challenges Coherus` deep discount for Humira biosimilar
15 Jun 2023 //
FIERCE PHARMA
Coherus BioSciences to launch Humira biosimilar at 85% discount
02 Jun 2023 //
REUTERS
Coherus Announces U.S. Launch of UDENYCA Autoinjector
22 May 2023 //
GLOBENEWSWIRE
Coherus & Junshi Announce Toripalimab Studies to be Presented at 2023 ASCO
27 Apr 2023 //
GLOBENEWSWIRE
Coherus lays off 20% of staff, while antimicrobial biotech makes deeper cuts
09 Mar 2023 //
ENDPTS
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI
13 Feb 2023 //
GLOBENEWSWIRE
Coherus pays out $32M for US commercialization rights to Eylea biosimilar
10 Jan 2023 //
ENDPTS
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea Biosimilar
09 Jan 2023 //
GLOBENEWSWIRE
